ESPE Abstracts

Growth hormone (GH) has been used for the treatment of short stature due to GH deficiency (GHD) for over 60 years. Height velocity (HV) in the first year of therapy is well studied and its crucial importance for growth outcome in subsequent years is confirmed.Objectives: The aim of this study is to assess the responsiveness to GH treatment in GHD patients of a newly established treatment center before and after change in starting GH dose...

Acid-labile subunit (ALS) is a glycoprotein, which is produced in the liver in response to growth hormone (GH). The main role of ALS is to form a complex with insulin-like growth factor I (IGF-I) and IGF binding protein-3 (IGFBP-3) in order to extend their circulating half-life and thus support the action of GH. Although the mechanism and the consequences of ALS deficiency are well studied, ALS-deficient patients are still of research interest because of the unclear incidence ...

Serum levels of insulin-like growth factor-1(IGF-1) are used universally for monitoring growth hormone (GH) therapy in patients with GH deficiency (GHD). However, the serum levels of IGF-1 are variable, therefore in the last years the serum levels of IGF binding protein-3 (IGFBP-3) and the molar ratio IGF-1/IGFBP-3 were introduced as more effective and stable parameters evaluating the safety and efficacy of GH treatment. Many studies present reference values of IGF-1, IGFBP-3 ...